false 0001100682 0001100682 2026-05-05 2026-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

May 5, 2026
Date of Report (Date of earliest event reported)

 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware 001-15943 06-1397316
(State or Other
Jurisdiction of Incorporation)
(Commission File Number) (IRS Employer
Identification No.)

 

251 Ballardvale Street
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices) (Zip Code)

 

781-222-6000
(Registrant’s Telephone Number, including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value CRL New York Stock Exchange

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”). The Board of Directors of the Company had previously approved and adopted the 2026 Incentive Plan on March 11, 2026, subject to the approval of the shareholders of the Company.

 

The material features of the 2026 Incentive Plan are described in detail under “Proposal 3 - Approval of the 2026 Long-Term Incentive Plan” of the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Proxy Statement”).

 

A copy of the 2026 Incentive Plan is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

At the Company’s Annual Meeting, the following proposals were adopted by the votes specified below. For more information on the following proposals, see the Company’s Proxy Statement.

 

(a) The following twelve (12) directors were elected to serve until our 2027 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:

 

  Number of Shares
Voted For
Number of Shares
Voted Against
Number of Shares
Abstained
Broker Non-Votes
Nancy C. Andrews 42,650,297 1,439,768 12,630 1,745,648
Steven Barg 43,590,311 493,258 19,126 1,745,648
Abraham Ceesay 35,798,426 8,288,770 15,499 1,745,648
Mark Enyedy 43,555,383 531,825 15,487 1,745,648
Birgit Girshick 44,023,112 67,096 12,487 1,745,648
Paul Graves 43,921,209 165,954 15,532 1,745,648
James C. Foster 43,504,046 580,009 18,640 1,745,648
Reshema Kemps-Polanco 42,762,359 1,325,991 14,345 1,745,648
George Llado, Sr. 43,433,616 624,853 44,226 1,745,648
Martin W. Mackay 43,893,349 195,758 13,588 1,745,648
Craig B. Thompson 43,544,080 543,155 15,460 1,745,648
Virginia M. Wilson 43,590,754 498,251 13,690 1,745,648

 

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

 

For Against Abstain Broker Non-Votes
41,356,139 2,716,251 30,305 1,745,648

 

(c) The shareholders approved the 2026 Long-Term Incentive Plan.

 

For Against Abstain Broker Non-Votes
41,523,179 2,561,994 17,522 1,745,648

 

(d) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2026.

 

For Against Abstain Broker Non-Votes
43,646,371 2,186,700 15,272 0

 

Computershare Trust Company, N.A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit  
Number Description
   
10.1 2026 Long-Term Incentive Plan
104 The cover page from this Current Report on Form 8-K, formatted as inline XBRL

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
     

Date:  May 11, 2026

By: /s/ Matthew L. Daniel
    Matthew L. Daniel, Corporate Senior Vice President,
    General Counsel, Corporate Secretary & Chief Compliance Officer

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 10.1

XBRL SCHEMA FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: dp246529_8k_htm.xml